Pyxis Oncology, Inc. Sustainability Profile
Pyxis Oncology, Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 2018, the company focuses on harnessing the power of monoclonal antibodies and other advanced technologies to create targeted treatments for various malignancies. With a commitment to addressing unmet medical needs, Pyxis Oncology has made significant strides in its research and development efforts, particularly in the realm of immuno-oncology. The company’s unique approach to drug development sets it apart in a competitive market, positioning it as a notable player in the oncology sector. As it continues to advance its pipeline of promising therapies, Pyxis Oncology remains dedicated to improving patient outcomes and redefining cancer treatment paradigms.
DitchCarbon Score
How does Pyxis Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pyxis Oncology, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pyxis Oncology, Inc.'s reported carbon emissions
Pyxis Oncology, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Pyxis Oncology may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it will be essential for Pyxis Oncology to consider developing and communicating its climate commitments to align with broader environmental goals.
How Carbon Intensive is Pyxis Oncology, Inc.'s Industry?
How Carbon Intensive is Pyxis Oncology, Inc.'s Location?
Pyxis Oncology, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pyxis Oncology, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
